RT Journal Article
SR Electronic
T1 The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
JF Pharmacological Reviews
JO Pharmacol Rev
FD American Society for Pharmacology and Experimental Therapeutics
SP 441
OP 461
DO 10.1124/pr.114.010215
VO 67
IS 2
A1 Judy R. van Beijnum
A1 Patrycja Nowak-Sliwinska
A1 Elisabeth J. M. Huijbers
A1 Victor L. Thijssen
A1 Arjan W. Griffioen
A2 Michael G. Rosenblum
YR 2015
UL http://pharmrev.aspetjournals.org/content/67/2/441.abstract
AB The concept of antiangiogenic therapy in cancer treatment has led to the approval of different agents, most of them targeting the well known vascular endothelial growth factor pathway. Despite promising results in preclinical studies, the efficacy of antiangiogenic therapy in the clinical setting remains limited. Recently, awareness has emerged on resistance to antiangiogenic therapies. It has become apparent that the intricate complex interplay between tumors and stromal cells, including endothelial cells and associated mural cells, allows for escape mechanisms to arise that counteract the effects of these targeted therapeutics. Here, we review and discuss known and novel mechanisms that contribute to resistance against antiangiogenic therapy and provide an outlook to possible improvements in therapeutic approaches.